Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1805 results
January 2016
-
Media ReleaseNovartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operationsStrong growth (cc) in full year sales, core operating income and core EPS[2] Net sales up 5% (cc) and core operating income up 10% (cc) Core operating income margin up 1.3 percentage points (…
-
Media ReleaseNovartis a enregistré, en 2015, une forte croissance des ventes et une hausse de sa marge core (tcc1) et annonce des plans pour accélérer la croissance d'Alcon et rationaliser les opérations du GroupeForte croissance (tcc) des ventes, du résultat opérationnel core et du BPA core[2] en 2015 Chiffre d'affaires net en hausse de 5% (tcc) et résultat opérationnel core en augmentation de 10% (tcc…
-
Media ReleaseNovartis erzielt 2015 eine kräftige Steigerung des Umsatzes und der Kern-gewinnmarge (kWk[1]); Pläne zur Wachstumsbeschleunigung bei Alcon und zur Straffung der Konzernaktivitäten bekannt gegebenSolides Wachstum (kWk) beim Umsatz, operativen Kernergebnis und Kerngewinn pro Aktie[2] im Gesamtjahr Der Nettoumsatz steigt um 5% (kWk), das operative Kernergebnis wächst um 10% (kWk) Die…
-
Rare speed on a rare disease
An investigational treatment for an uncommon immunodeficiency disease races into clinical studies.
-
Featured NewsNovartis moves to address superbug threat
Novartis and other industry leaders call for action to address antimicrobial resistance, one of the world’s most serious public health challenges
-
How to address the culture gap between academia and industry in biomedicine
Experts call for significant changes to facilitate the discovery of new treatments.
-
Media ReleaseNovartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the USCosentyx is the first and only interleukin-17A (IL-17A) inhibitor approved for adult patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) FDA approval for Cosentyx is…
-
Media ReleaseNovartis continues to grow immuno-oncology pipeline through collaboration and licensing agreement with Surface OncologyAgreement gives Novartis access to four pre-clinical programs that target regulatory T cell populations, inhibitory cytokines, and immunosuppressive metabolites in the tumor microenvironment…
-
Media ReleaseNovartis Pharmaceuticals collaborates with Qualcomm in digital innovation with the Breezhaler(TM) inhaler device to treat COPDThe Breezhaler(TM) inhaler is the device for Novartis' portfolio of COPD treatments of Onbrez and Seebri, and Ultibro, the leading LABA/LAMA treatment The collaboration further supports Novartis'…
-
In The NewsA new era of healthcare innovationWe are experiencing a new wave of innovation in health care – one that promises to create the smartest, most connected, and most efficient health systems the world has ever seen.
December 2015
-
Media ReleaseNovartis announces NEJM publication of two major trials showing significant efficacy of Cosentyx in ankylosing spondylitis patientsCosentyx (secukinumab) is the first IL-17A inhibitor approved in Europe to treat ankylosing spondylitis (AS) and first treatment advance in 16 years since anti-tumor necrosis factor (anti-TNF)…
-
Media Release300 million child-friendly antimalarial treatments supplied without profit by NovartisCoartem® Dispersible*, the first WHO prequalified[1] pediatric antimalarial treatment, has become the standard of care in over 30 malaria-endemic countries Since 2009, Novartis has supplied 300…
Pagination
- ‹ Previous page
- 1
- …
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- …
- 151
- › Next page